“On July 5, 2022, FDA administratively stayed the marketing denial order,” the agency’s tobacco division wrote in a tweet. “The agency has determined that there are scientific issues unique to the JUUL application that warrant additional review.”
“This administrative stay temporarily suspends the marketing denial order during the additional review but does not rescind it,” FDA Tobacco said in its Twitter thread.
“All electronic nicotine delivery systems, or ENDS products, including those made by JUUL, are required by law to have FDA authorization to be legally marketed,” FDA Tobacco concluded. “The stay and the agency’s review does not constitute authorization to market, sell, or ship JUUL products.”
Keep reading at The Hill for more.